Next Article in Journal
Evaluation of the Dentinal Shear Bond Strength and Resin Interface in Primary Molars after Pre-Treatment with Various Dentin Bio-Modifiers: An In Vitro Study
Next Article in Special Issue
Polycarbonate-Based Copolymer Micelles as Biodegradable Carriers of Anticancer Podophyllotoxin or Juniper Extracts
Previous Article in Journal
Reconstructive Approach in Residual Periodontal Pockets with Biofunctionalized Heterografts—A Retrospective Comparison of 12-Month Data from Three Centers
Previous Article in Special Issue
Role of the Lactide:Glycolide Ratio in PLGA Nanoparticle Stability and Release under Lysosomal Conditions for Enzyme Replacement Therapy of Lysosomal Storage Disorders
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Superfluorinated, Highly Water-Soluble Polyphosphazenes as Potential 19F Magnetic Resonance Imaging (MRI) Contrast Agents

1
Institute of Polymer Chemistry, Johannes Kepler University Linz, Altenberger Straße 69, 4040 Linz, Austria
2
Department of Biomedical Imaging and Image-Guided Therapy, Division of Structural and Molecular Preclinical Imaging, Medical University of Vienna and General Hospital of Vienna, 18-20 Währinger Gürtel, 1090 Vienna, Austria
*
Authors to whom correspondence should be addressed.
J. Funct. Biomater. 2024, 15(2), 40; https://doi.org/10.3390/jfb15020040
Submission received: 4 December 2023 / Revised: 5 February 2024 / Accepted: 7 February 2024 / Published: 10 February 2024
(This article belongs to the Special Issue Synthetic Polymers for the Delivery of Vaccines and Therapeutics)

Abstract

:
“Hot spot” 19F magnetic resonance imaging (MRI) has garnered significant attention recently for its ability to image various disease markers quantitatively. Unlike conventional gadolinium-based MRI contrast agents, which rely on proton signal modulation, 19F-MRI’s direct detection has a unique advantage in vivo, as the human body exhibits a negligible background 19F-signal. However, existing perfluorocarbon (PFC) or PFC-based contrast materials suffer from several limitations, including low longitudinal relaxation rates and relatively low imaging efficiency. Hence, we designed a macromolecular contrast agent featuring a high number of magnetically equivalent 19F-nuclei in a single macromolecule, adequate fluorine nucleus mobility, and excellent water solubility. This design utilizes superfluorinated polyphosphazene (PPz) polymers as the 19F-source; these are modified with sodium mercaptoethanesulfonate (MESNa) to achieve water solubility exceeding 360 mg/mL, which is a similar solubility to that of sodium chloride. We observed substantial signal enhancement in MRI with these novel macromolecular carriers compared to non-enhanced surroundings and aqueous trifluoroacetic acid (TFA) used as a positive control. In conclusion, these novel water-soluble macromolecular carriers represent a promising platform for future MRI contrast agents.

Graphical Abstract

1. Introduction

Classical magnetic resonance imaging (MRI) is an unprecedented clinical imaging modality used to diagnose and monitor numerous pathologies in vivo. To improve MR sensitivity and specificity, the era of contrast-enhanced MRI (CE-MRI) has offered groundbreaking insights into the delineation of benign and malignant lesions covering all parts of the body, assessment of perfusion [1], evaluation of response to anti-angiogenic therapies [2,3,4,5,6,7,8], as well as the prediction of outcomes after chemotherapy. Contrast agents (CAs), which are used in a clinical setting and which improve diagnostic accuracy, are exclusively small, hydrophilic gadolinium(III) (Gd(III))-based chelates. The currently clinically available Gd(III) agents are specifically designed to move through patients passively, with little or no interaction with proteins or cells, and provide superb contrast to differentiate anatomical structures and characterize pathophysiology. However, this occurs in a nonspecific manner (by interactions with protons present in the living body) [9]. Furthermore, Gd(III)-based contrast agents are contraindicated in patients with acute and chronic renal insufficiency [10]. In addition, recent studies have reported the deposition of free Gd(III) in neural tissue, bones and muscles in patients who have undergone systemic CE-MRI [11,12]. Thus, there is an urgent clinical need for alternative MRI contrast agents that are acceptable in the context of renal insufficiency.
Non-proton or X-nuclei MRI is based on the detection of the nuclei of other atoms (X-nuclei) in the body, such as sodium (23Na), phosphorus (31P), chlorine (35Cl), potassium (39K), deuterium (2H), oxygen (17O), lithium (7Li), and fluorine (19F), using modified software and hardware. In addition, X-nuclei MRI can provide fundamental, new metabolic information related to cellular energetic metabolism and ion homeostasis in tissues that cannot be assessed using standard proton MRI. In particular, 19F has numerous attractive properties, such as 100% natural abundance and a negligible 19F background signal in tissues, prompting extensive research into 19F-MRI probes [13]. In addition, it allows for quantitative detection of distinct molecular targets in vivo due to the broad chemical shift range in nuclear magnetic resonance (NMR) of various organofluorine species applied as signal enhancers for 19F-MRI [14]. Thereby, 19F-MRI is an emerging modality, predominantly for spectral molecular imaging and cell tracking. However, the sensitivity of 19F-MRI remains a challenge, as the local 19F concentration cannot come close to the 1H content present in the human body. Thus, 19F-MRI CAs that provide high fluorine content and good water solubility are required to reach detectable 19F concentrations in vivo. Several fluorinated probes for in vivo 19F-MRI have been reported to date, most of them based on liquid perfluorocarbons (PFCs) and perfluoropolyether (PFPE) nanoemulsions used for quantitative imaging of transplanted cells, angiogenesis or inflammation [15]. Nevertheless, these investigated current exogenous probes, such as PFCs and PFPEs, have been solely used for cell tracking and their in vivo application is strongly limited due to their hydrophobicity [15,16]. Furthermore, the sensitivity of 19F-MRI remains a challenge, as the local 19F concentration cannot approach the 1H content present in the human body by far. Thus, 19F-MRI CAs that provide high fluorine content are required to reach detectable 19F concentrations in vivo. Furthermore, PFC-nanoparticles have been investigated for the mapping of tumor oxygenation [16]. However, these formulations require distinctly high concentrations to enable detection by MRI. The need for auxiliary surfactants and the multiple resonance frequencies account for additional shortcomings [17,18,19]. Alternative approaches employ the design of specific fluorinated monomers, incorporated in macromolecular structures by controlled polymerization methods such as RAFT [20,21] or ROMP [19]. Thereby, co-polymerization or post-polymerization reactions provide additional functionality or water solubility.
Poly(organo)phosphazenes (PPz) represent a versatile family of hybrid polymers that combine organic and inorganic components [22,23]. These polymers feature a highly flexible inorganic backbone composed of [NPR2]n repeat units. They are of high interest in the field of biomedicine, with potential applications such as stent coatings, drug and protein delivery systems, and vaccine adjuvants [24,25]. The controlled synthesis of these polymers, primarily through living cationic polymerization methods, allows for the creation of polymers with precisely controlled length and a narrow range of characteristics (referred to as Ð) [26,27]. Subsequently, various modification reactions can be employed after polymerization to fine-tune the functionality, degradability, and overall architecture of PPz. Indeed, trifluoroethoxypolyphosphazene has gained FDA approval, for example, in the form of so-called polyzene-F nanocoatings on embolic spheres and coronary stents, and is progressing to advanced clinical trials in Europe; the same has occurred for microbeads used in cancer therapy [28]. Concurrently, there has been significant progress in the development of degradable polyphosphazenes for use as versatile drug and vaccine carriers [25,29,30,31]. These polyphosphazenes possess the unique qualities of degradability, high water solubility, and multifunctionality. In this study, we report for the first time on the synthesis and evaluation of novel superfluorinated yet highly water-soluble PPz as a tunable platform for the design of next-generation Gd(III)-free MRI contrast agents.

2. Materials and Methods

Chemicals were purchased from different commercial sources and used as received, unless stated otherwise. Deuterium oxide (D2O) and deuterated acetone ((CD3)2CO) were purchased from Deutero, anhydrous LiBr from Alfa Aesar and HPLC-grade dimethylformamide (DMF) from Fisher Chemicals (Schwerte, Germany). Trifluoroacetic acid (TFA), ≥99% p.a., phosphate-buffered saline (PBS) and fetal bovine serum (FBS) used in 19F-MRI, as well as 2,2,2-trifluoroethanol, 4-(diphenylphosphino)styrene, 2,2-dimethoxy-2-phenylacetophenone (DMPA), hexachloroethane, sodium 2-mercaptoethanesulfonate (MESNa) and propargyl alcohol were bought from Sigma Aldrich (St. Louis, MO, USA) and NaH from Sigma Aldrich or BLDpharm (Shanghai, China). Anhydrous dichloromethane (DCM) and anhydrous tetrahydrofuran (THF) were obtained from Thermo Scientific (Waltham, MA, USA) and ethanol (EtOH), methanol (MeOH) and n-heptane from VWR (Radnor, IN, USA). PBS (phosphate-buffered saline) buffers were prepared from PBS tablets from VWR and the pH was adjusted accordingly with NaOH or HCl. The polyphosphazene monomer, Cl3PNSiMe3, was synthesized according to the literature and routine laboratory procedures [31,32].
Nuclear magnetic resonance (NMR) spectra were recorded on a Bruker Avance III 300 MHz spectrometer in deuterated solvents at 25 °C. IR (infra-red) spectra were measured with a PerkinElmer 100 Series FT-IR spectrometer equipped with ATR using a scan number of 128. Size exclusion chromatography (SEC) in organic media was performed on a Viscotek GPCmax instrument (Malvern Panalytical, Malvern, UK) using a PFG column from Polymer Standard Service GmbH (PSS) (Mainz, Germany) (300 mm × 8 mm, 5 µm particle size). The samples were filtered through 0.2 µm PTFE syringe filters prior to injection and eluted with DMF containing 10 mM LiBr as the mobile phase at a flow rate of 0.75 mL min−1 at 60 °C. The molecular weights were measured using a conventional calibration of the refractive index detector, calibrated with polystyrene standards from Polymer Standard Service GmbH (PSS). Dynamic light scattering (DLS) measurements were performed on a Malvern Zetasizer Nano ZSP at 25 °C at a fixed scattering angle of 173°. The sample solutions (0.2 mg mL−1) were prepared in PBS pH 7.4, sonicated for 10 min and filtered through 0.2 µm nylon syringe filters prior to the measurement. The zeta potential was determined using a Zetasizer Nano-ZS from Malvern (Malvern Panalytical, Malvern, UK) in nanopure water as dispersant (viscosity = 0.8872 cP and refractive index, RI = 1.330), calibrated with a Zeta Potential transfer standard (−40 ± 5.8 mV). Sample preparation was analogous to DLS measurements with a sample concentration of 0.5 mg mL−1. Thiol–yne reactions were performed at 5 °C in a photochemical reactor from Rayonet (Southern New England Ultraviolet, Branford, CT, USA) using UV light with a wavelength of 365 nm. Dialysis was carried out using Spectrum Spectra/Por RC membrane tubing with 1 kDa molecular weight cut-offs (MWCOs). EtOH used as a solvent was recycled by distillation. Samples were lyophilized with an Alpha 1–2 LDplus freeze-drying system from Christ.
All magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) measurements were performed using a 9.4 T (BioSpec 94/30 USR, Avance Neo, Bruker, Ettlingen, Germany) horizontal bore small animal MR Scanner along with a 12 cm shielded gradient (BGA12) running Paravision 360.3.3 software (Bruker BioSpec, Ettlingen, Germany). A special double-tuned 1H/19F (400.2/376.8 MHz) transmit–receive surface coil (RF SUC 400 1H/19F ID = 20 L/L TR Bruker BioSpec, Ettlingen, Germany) with an inner shell diameter of 20 mm was used for both MRI and MRS measurements. To determine the contrast agent relaxivity (r1), serial dilutions of the prepared superfluorinated PPz probe were performed in PBS (pH = 7.4). Beginning with a concentration of 11.1−3 M, a series of dilutions was prepared in order to establish an optimal concentration range for the detection of the 19F MR signal. As a reference substance, PBS was used to calculate the signal-to-noise ratio (SNR) and 1 mM aqueous TFA solution was used as a positive control. Five dilutions ranging from 11.1 mM to 1.11 mM in Milli-Q water with a volume of 0.3 mL were prepared. All samples were measured in Eppendorf safe-lock polypropylene PP-tubes with a diameter of 0.5 cm. The tubes were placed in the center of a plastic box and measured at ambient temperature. For the quantitative evaluation of the SNR, regions of interest (ROIs) were placed inside each PP-tube and in the surroundings (noise). The resonance frequency and the corresponding 90-degree flip angle for the material were determined beforehand. A basic MRS spectrum was performed using an ISIS (Image Selected In vivo Spectroscopy) sequence to determine the correct resonance frequency and the AdjRefPowX procedure (part of the Paravision 360.3.3 software) was used to determine the correct reference power corresponding to a pulse with a 90-degree flip angel. Briefly, in this procedure, depending on the coil hardware (continuous wave power of the coil, in our case 1 W), radio frequency pulses of increasing length are applied and their amplitude is measured. The maximum value in a certain range is then defined as the reference power needed to achieve a flip angle of 90 degrees.
19F-MRI was carried out using a gradient echo fast low-angle shot (FLASH) sequence with an echo time of TE = 1.5 ms, a repetition time TR = 300 ms, a flip angle of 90 degrees and a slice thickness of 5 mm, as well as a matrix size of 32 × 32 and a field of-view (FOV) = 20 × 20 mm. Averaging over 100 scans resulted in a total acquisition time of 16 min. The sample solutions were measured in an Eppendorf vial and the ROIs were drawn according to the outline of the vials.
19F-MRS spectra were obtained via an image-selected in vivo spectroscopy sequence (ISIS). ISIS is recommended for short T2 nuclei in combination with the used transmit surface coil. The main parameters were TR = 2000 ms and 1024 acquisition points. Using a bandwidth of 18 kHz and a center frequency of −74 ppm resulted in an acquisition time of 5 min.

2.1. Synthesis of Poly(trifluoroethoxy-propargyloxy)phosphazene (TFE-Propargyl-PPz, P1)

PPz P1 was synthesized in an argon-filled glove box according to an adapted literature procedure [26,27]. Briefly, 4-(diphenylphosphino)styrene (30.0 mg, 0.104 mmol, 1 eq.) was dissolved in ≈1 mL dry DCM and reacted with hexachloroethane (27.1 mg, 0.115 mmol, 1.1 eq.) in ≈1 mL dry DCM for 24 h. The chlorinated initiator was then added to the PPz-monomer Cl3PNSiMe3 (1.7521 g, 7.804 mmol, 75 eq) in ≈3 mL DCM and polymerization was carried out over 24 h. In parallel, 2,2,2-trifluoroethanol (1.18 mL, 15.6 mmol, 150 eq.) and propargyl alcohol (0.45 mL, 7.8 mmol, 75 eq.) were dissolved in approximately 50 mL anhydrous THF and 0.9364 g NaH (23.41 mmol, 225 eq.) was added portion-wise, avoiding excessive gas evolution and heating, and stirred in the glove box for 24 h. Afterwards, the polymer solution was added to the deprotonated alcohols in THF, resulting in a slightly turbid solution, and stirred for additional 24 h. The resulting poly(organo)phosphazene was transferred out of the glove box, the solvent was evaporated and the polymer was purified by precipitation from THF in 2x deionized water and 2x heptane. After drying in a desiccator, an off-white waxy polymer was obtained (1.336 g, 79%).
1H-NMR (300MHz, (CD3)2CO, δ): 3.15 (br, 44H), 4.55 (br, 196H), 4.77 (br, 94H), 5.47 (d, 1H), 6.03 (d, 1H), 6.87 (dd, 1H), 7.60–7.91 (m, 14H) ppm; 31P{1H}-NMR (121 MHz, (CD3)2CO, δ): −8.12, −7.16, −3.07, 16.64 ppm; 19F-NMR (282 MHz, (CD3)2CO, δ): −75.73 ppm.

2.2. Synthesis of Poly(trifluoroethoxy-propargyloxy-MESNa)phosphazene (TFE-MESNa-PPz, P2)

The PPz P1 was further reacted via a thiol–ene reaction [27]. TFE-Propargyl-PPz (209.4 mg, 2.339 mmol, 1 eq.) was dissolved in 25 mL MeOH in a quartz flask and sodium 2-mercaptoethanesulfonate (656 mg, 3.92 mmol, 4 eq.) and DMPA (21 mg, 0.08 mmol, 10 wt%) were added as the photoinitiator. After degassing with Ar for 10 min, the flask was put in an UV reactor and irradiated at 365 nm at 5 °C overnight. Subsequently, the solvent was evaporated and the product dialyzed against deionized H2O and EtOH (1kDa MWCO) for 48 h. After freeze-drying, a white fluffy solid was obtained (173.8 mg, 41%).
1H-NMR (300MHz, D2O, δ): 2.32–3.59 (br, 16H), 4.31 (br, 18H) ppm; 31P{1H}-NMR (121 MHz, D2O, δ): −7.56, 2.13 ppm; 19F-NMR (282 MHz, D2O, δ): −75.81 ppm.

3. Results and Discussion

3.1. Polymer Synthesis and Characterization

A superfluorinated yet water-soluble polyphosphazene was designed to fulfil the proposed prerequisites for ideal 19F-MRI probes, namely a high local concentration of magnetically equivalent 19F-nuclei, high mobility of the fluorine nucleus, excellent aqueous solubility and biocompatibility [13]. We selected a polyphosphazene platform not only due to the extensive track record of PPz in biomedical applications but also the unique chemical constitution, [NPR2]n, of these polymers. This unique [NPR2]n structure allows high loading, with its two functionalizable groups per repeat unit combined with an inherent high mobility of the pendant fluorine moieties. This high mobility is due to the unique structure’s ultra-low intrinsic barrier to rotation in the main chain. In fact, polydifluorophosphazene is the lowest ever calculated for skeletal bonding in polymers [33]. To realize this polymer design, a poly(dichloro)phosphazene [NPCl2]n was synthesized via phosphine-mediated living cationic polymerization, employing 4-(diphenylphosphino)styrene as an initiator and Cl3PNSiMe3 as a monomer in a ratio 1:75, according to procedures previously developed in our laboratory [26]. Subsequently, 0.67 eq. of the pendant chlorine atoms were substituted with 2,2,2-trifluoroethanol (TFE) moieties to functionalize each phosphorus atom in the main chain at least once (Scheme 1).
Trifluoroethanol was selected to provide three identical 19F-nuclei per molecule, showing a single and distinct signal in 19F-NMR spectroscopy at around −75 ppm (Figure 1). The remaining highly labile chlorine atoms were substituted with propargyl alcohol for subsequent post-polymerization modifications yielding P1 as a macromolecular intermediate, as shown in Scheme 1a. This intermediate was thoroughly characterized by NMR spectroscopy, showing the targeted ratio of TFE to propargyl alcohol of 2:1, as well as the approximate desired chain length with 73 repeating units as calculated from the aromatic protons of the phosphine end-group (Figure S1). As expected, the 19F-NMR spectrum shows the distinct peak of the trifluoroethoxy group at around −75 ppm, and the 31P-NMR spectrum gives the characteristic peak of the polyphosphazene backbone, demonstrating complete substitution of the backbone chlorine atoms (Figure 1a,b). In addition, the end-groups of the polymer chain were identified by 1H-31P—heteronuclear multiple bond correlation (HMBC) 2D-NMR spectroscopy Figure S7. The phosphorus signal corresponding to the α-chain end clearly correlates with the signals of the aromatic protons. The polymer was further characterized by SEC measurements in organic solvent (DMF), showing a single symmetric peak with a molecular weight of around 15 kDa and narrow dispersity of Đ = 1.1, Figure 2a.
To provide the desired water solubility of the final superfluorinated PPz, the triple bonds of the propargyl alcohol substituents were reacted with sodium 2-mercaptoethane sulfonate (MESNa) in a thiol–yne addition reaction, yielding the final TFE-MESNa-PPz P2 (Scheme 1b). The quantitative conversion of the triple bonds was verified by FTIR spectroscopy, showing the complete disappearance of the band assigned to the triple-bond signal at around 2130 cm−1. Furthermore, 1H-NMR spectroscopy displayed the new signals of the methylene groups stemming from the triple-bond and the coupled MESNa moieties (Figures S4 and S8). Although the distinct assignment of the signals was not possible in the 1H-NMR spectrum due to overlapping signals and extensive peak broadening, the ratio between the signals of the substituents and the overall integrals could be assigned to the correct substitution pattern on polymer P2. In addition, a stable polyphosphazene backbone structure and the presence of suitable 19F-nuclei could be confirmed by the 19F- and 31P-NMR spectra (Figure 1a,b). SEC measurements of the sulfonated polymer showed an increase in Mn to around 30 kDa (Figure 2a), and DLS measurements and zeta potential analysis were performed as well. The average ζ-potential was measured at −12.5 mV in triplicate (Figure S9); however, the split signal of the triplicate measurements might indicate a slight agglomeration of the polymer at the respective concentration. This was further investigated by DLS measurements in PBS at pH 7.4, where a diameter of Dh = 5.9 nm according to its volume distribution could be determined (Figure 2b), further supporting the low degree of agglomeration suggested by the zeta potential analysis. The relatively small hydrodynamic diameter is to be expected, since no particulate formulation is present; only completely soluble linear polymers, as characterized by SEC. Overall, the prepared novel 19F-MRI CA displays only magnetically equivalent 19F-nuclei, a fluorine content of over 290 19F-nuclei per polymer chain (17.5 wt% 19F on P2) and excellent water solubility in the range of NaCl (>360 mg mL−1) in PBS pH 7.4. Furthermore, they retain their high water-solubility even at lower pH with >100 mg mL−1 at pH 3.

3.2. Magnetic Resonance Imaging (MRI) and Spectroscopy (MRS)

The resonance frequency as well as the corresponding 90-degree flip angle of P2 was calibrated for the ensuing MRI and MRS experiments. This was performed using the preprogrammed AdjRefPowX procedure, increasing the radio frequency pulse length and observing the corresponding signal amplitude. The coil and setup were tested in advance, using a cylindrical phantom containing a 1M aqueous trifluoroacetic acid (TFA) solution as a reference substance and positive control, showing a peak maximum at −76.1 ppm [34] in the 19F-spectra recorded by ISIS measurement. Using a sampling resolution of 89.268 μs at a pulse power of 1 W (7.071 V), the maximum was found at a pulse length of 407.243 μs (Figure S10), giving a reference power of 0.166 W to achieve a 90-degree flip angle for TFA. For P2, the peak maximum in the corresponding 19F-spectrum was recorded at −76.7 ppm according to ISIS measurements (Figure S11a). In contrast to the positive control TFA, a slightly lower sampling resolution of 77.778 μs was used to evaluate the 90-degree flip angle and the absolute maximum was found at a pulse length of 361.111 μs for a pulse power of 1 W (7.071 V), Figure S11b, giving a reference power of 0.13 W for the TFE-MESNa-PPz.
To evaluate the quantification of the novel contrast agent P2, dilution series of the TFE-MESNa-PPz in PBS pH7.4, as well as in fetal bovine serum (FBS), were prepared. 19F-MRI measurements were performed using a FLASH sequence for imaging, including the correct adjustment values determined above. The samples were prepared in 1 mL Eppendorf vials and the regions of interest (ROIs) drawn on the outline of the vials. As a control, the same size ROI was selected to determine the noise (Figure 3a,b). Based on these measurements, the mean signal intensity (mSI) of the ROI as well as the standard deviation (Std) were determined for every concentration and the signal-to-noise ratio (SNR) was calculated for both (Figure 3c,d). With a reasonable SNR of approximately 8 and 13 for the mSI and Std, respectively, a lower limit of 4.47 mM P2 was required in PBS. For the dilutions in FBS, the lowest SNR evaluated was 3.5 and 6.5 for the mSI and Std of 3.8 mM TFE-MESNa-PPz. The increase in SNR correlating to the increased concentration of the TFE-MESNa-PPz can be seen in Figure 3c,d (red), showing an SNR of around 22 and 23, based on the STD, for the maximum tested concentration of 11.1 mM in PBS and 16.7 mM tested in FBS. As already stated, the signal intensity from a 19F MR image is directly proportional to the fluorine concentration, allowing quantitative “hot spot” MRI. Hence, a decrease in the signal intensity with the decreasing concentration of P2 was observed. Furthermore, our results show a difference in mSI when using PBS or FBS as media. In particular, at 11.1 mM the mean signal intensity was 6864.73 for the sample in PBS and at 4984.75 for P2 dissolved in FBS, which corresponds to a factor of approximately 1.4. At the lowest P2 concentrations of 4.47 and 3.8 mM, in PBS and FBS, respectively, the mSI decreased approximately five times. Generally, a large number of 19F atoms is required in each voxel of the target volume in order to enable high conspicuity in 19F-MRI explaining the observed signal decrease with decreasing concentration. In addition, agglomeration with proteins present in serum can occur, which can cause differences in the chemical surroundings of the fluorine atoms, thus weakening the MRI signal as well. Although investigations regarding the relaxivities of GBCAs in different media as well as at different magnetic field strengths have been conducted [35,36], to the best of our knowledge, these are the first results evaluating the relaxivity of superfluorinated polymers in two different solvents. In accordance with the MRI measurements, the spectra recorded by MRS, using an ISIS sequence, showed an analogous increase in peak intensity with the increasing concentration of P2 (Figure S12).
Overall, the prepared TFE-MESNa-PPz contrast agent showed high-intensity MRI signals on the phantom images (Figure 3a,b). Considering the acquisition time of about 16 min and an SNR of eight, a detection threshold of approximately 8.75 × 1016 19F-nuclei per voxels could be estimated for the novel 19F contrast agent TFE-MESNa-PPz P2. The same detection threshold was reported by Tirotta et al. using a superfluorinated Perfecta-based nanoemulsion as MRI probe [37], though with a significantly different acquisition time of approx. 1 h and a SNR of 3.5. Further reports on the analysis of T1 and T2 relaxation times on fluorinated samples suggest the possibility of obtaining images with high SNR using fast sequences [38,39]. Thus, our future work will not only target the systematic evaluation of the already described material by additional advanced pulse sequences available for 19F imaging experiments but also further development of the modular PPz-system in order to achieve shorter acquisition times together with high SNR.

4. Conclusions

Optimal 19F-MRI contrast agents are expected to provide a high number of magnetically equivalent 19F-nuclei to enable a sufficiently high signal-to-noise ratio, in combination with sufficient 19F-nuclei mobility and excellent water solubility [13,40]. While most used 19F-MRI agents have a fluorine content ranging from 17 fluorine atoms for perfluorooctyl bromide up to 40 fluorine atoms for perfluoropolyethers, we herein reported the synthesis of a new superfluorinated polyphosphazene 19F-MRI probe bearing over 290 magnetically equivalent 19F-nuclei per macromolecule and, hence, a fluorine content of approximately 17 wt%. Furthermore, these sulfonated derivatives of trifluoroethoxypolyphosphazene showed excellent water solubility of >360 mg mL−1, which is important for subsequent in vivo administration. The polymers showed a narrow dispersity of Đ = 1.1 and an average hydrodynamic diameter of 5.9 nm. With their very high fluorine content, our proposed 19F-MRI CAs show a single intense resonance peak in both 19F-MRS and MRI, avoiding any possible artefacts and misidentifications. The MRI performances and SNRs strongly indicate their exceptional capabilities as new 19F-MRI CAs for in vivo applications. Furthermore, due to the ease of tuneability on the PPz platform, the herein described TFE-MESNa-PPz 19F-MRI contrast agents hold great potential to evolve from simple hot-spot 19F imaging to a multifunctional platform, including multimodal imaging, diagnosis, and therapy integration.

Supplementary Materials

The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/jfb15020040/s1, Figure S1: 1H-NMR spectrum of TFE-Propargyl-PPz P1 in (CD3)2CO, including peak assignment; Figure S2: 31P-NMR spectrum of TFE-Propargyl-PPz P1 in (CD3)2CO; Figure S3: 19F-NMR spectrum of TFE-Propargyl-PPz P1 in (CD3)2CO; Figure S4: 1H-NMR spectrum of TFE-MESNa-PPz P2 in D2O; Figure S5: 31P-NMR spectrum of TFE-MESNa-PPz P2 in D2O; Figure S6: 19F-NMR spectrum of TFE-MESNa-PPz P2 in D2O; Figure S7. 1H-31P—heteronuclear multiple bond correlation (HMBC) spectrum of TFE-Propargyl-PPz P1 in (CD3)2CO. The spectrum confirms a correlation between the aromatic protons and the phosphorus atom of the phosphine end-group at around 17 ppm (orange). Additionally, the phosphorus signal at around −7.5 ppm can be assigned to the repeating units of the polymer (violet) and the signal at around −2.8 ppm to the opposite chain end (green); Figure S8: FT-IR spectra of TFE-Propargyl-PPz P1 and TFE-MESNa-PPz P2 showing complete disappearance of the signal corresponding to the triple bond at around 2130 cm−1, highlighted in green; Figure S9: Evaluation of zeta-potential of TFE-MESNa-PPz. Measurement was carried out in triplicates (blue, black and red) and in nanopure water as a dispersant (viscosity = 0.8872 cP and refractive index, RI = 1.330) after calibration with Zeta Potential Transfer Standard (−40 mV ± 5.8 mV) showing an average ζ-potential of −12.5 mV ± 0.8 mV; Figure S10: Flip angle graph for TFA as a positive control: a) Isolated peak of TFA in a 19F-spectrum recorded via an ISIS spectroscopy sequence. b) Dependence of the signal amplitude of TFA at -76.1 ppm on radio frequency pulse length, as determined by the AdjRefPowX procedure, showing the maximum at a pulse length of 407.243 μs; Figure S11: Evaluation of the 90-degree flip angle of P2. a) Isolated peak of P2 in a 19F-spectrum recorded via an ISIS spectroscopy sequence. b) Dependence of the signal amplitude of P2 at −76.7 ppm on radio frequency pulse length, as determined by the AdjRefPowX procedure, showing the maximum at a pulse length of 361.111 μs; Figure S12: Quantitative evaluation of TFE-MESNa-PPz by MRS, based on the arbitrary peak intensity at −76.6 ppm in the respective 19F-spectra using an ISIS spectroscopic sequence.

Author Contributions

P.S.: Methodology, data curation, formal analysis, investigation, writing—original draft, writing—review and editing. V.S.: Investigation and data curation. J.F.: Investigation, data curation, formal analysis, software, validation, writing—original draft, writing—review and editing. T.H.H.: Supervision, resources, writing—review and editing. O.B.: Resources, writing—review and editing. I.T.: conceptualization, supervision, resources, methodology, writing—review and editing. I.P.-M.: Conceptualization, project administration, methodology, data curation, formal analysis, investigation, writing—original draft, writing—review and editing. All authors have read and agreed to the published version of the manuscript.

Funding

The authors acknowledge the financial support of the Austrian Science Fund project (FWF), T 1145-B (awarded to I.P-M) and project FWF P 36208 (awarded to I.T).

Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Runge, V.M. Notes on “Characteristics of Gadolinium-DTPA Complex: A Potential NMR Contrast Agent”. Am. J. Roentgenol. 2008, 190, 1433–1434. [Google Scholar] [CrossRef]
  2. Gries, H.; Rosenberg, D.; Weinmann, H.J. Paramagnetic complex salts, their preparation, and their use in NMR-diagnostics. ZA825313B, 25 May 1987. [Google Scholar]
  3. Weinmann, H.J.; Brasch, R.C.; Press, W.R.; Wesbey, G.E. Characteristics of gadolinium-DTPA complex: A potential NMR contrast agent. AJR Am. J. Roentgenol. 1984, 142, 619–624. [Google Scholar] [CrossRef] [PubMed]
  4. Runge, V.M.; Clanton, J.A.; Price, A.C.; Herzer, W.A.; Allen, J.H.; Partain, C.L.; James, A.E.; Dyke Award, J.R. Evaluation of contrast-enhanced MR imaging in a brain-abscess model. AJNR Am. J. Neuroradiol. 1985, 6, 139. [Google Scholar] [PubMed]
  5. Bui-Mansfield, L.T. Top 100 Cited AJR Articles at the AJR’s Centennial. Am. J. Roentgenol. 2006, 186, 3–6. [Google Scholar] [CrossRef] [PubMed]
  6. Laniado, M.; Weinmann, H.J.; Schörner, W.; Felix, R.; Speck, U. First use of GdDTPA/dimeglumine in man. Physiol. Chem. Phys. Med. NMR 1984, 16, 157–165. [Google Scholar] [PubMed]
  7. Weinmann, H.J.; Laniado, M.; Mützel, W. Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol. Chem. Phys. Med. NMR 1984, 16, 167–172. [Google Scholar] [PubMed]
  8. Lohrke, J.; Frenzel, T.; Endrikat, J.; Alves, F.C.; Grist, T.M.; Law, M.; Lee, J.M.; Leiner, T.; Li, K.-C.; Nikolaou, K.; et al. 25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future Perspectives. Adv. Ther. 2016, 33, 1–28. [Google Scholar] [CrossRef] [PubMed]
  9. Wahsner, J.; Gale, E.M.; Rodríguez-Rodríguez, A.; Caravan, P. Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers. Chem. Rev. 2019, 119, 957–1057. [Google Scholar] [CrossRef] [PubMed]
  10. Schieda, N.; Blaichman, J.I.; Costa, A.F.; Glikstein, R.; Hurrell, C.; James, M.; Jabehdar Maralani, P.; Shabana, W.; Tang, A.; Tsampalieros, A.; et al. Gadolinium-Based Contrast Agents in Kidney Disease: A Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists. Can. J. Kidney Health Dis. 2018, 5, 136–150. [Google Scholar] [CrossRef]
  11. Iyad, N.; Ahmad, M.S.; Alkhatib, S.G.; Hjouj, M. Gadolinium contrast agents- challenges and opportunities of a multidisciplinary approach: Literature review. Eur. J. Radiol. Open 2023, 11, 100503. [Google Scholar] [CrossRef]
  12. Runge, V.M. Critical Questions Regarding Gadolinium Deposition in the Brain and Body After Injections of the Gadolinium-Based Contrast Agents, Safety, and Clinical Recommendations in Consideration of the EMA’s Pharmacovigilance and Risk Assessment Committee Recommendation for Suspension of the Marketing Authorizations for 4 Linear Agents. Investig. Radiol. 2017, 52, 317–323. [Google Scholar] [CrossRef]
  13. Mo, Y.; Huang, C.; Liu, C.; Duan, Z.; Liu, J.; Wu, D. Recent Research Progress of 19 F Magnetic Resonance Imaging Probes: Principle, Design, and Their Application. Macromol. Rapid Commun. 2023, 44, 2200744. [Google Scholar] [CrossRef] [PubMed]
  14. Schmieder, A.H.; Caruthers, S.D.; Keupp, J.; Wickline, S.A.; Lanza, G.M. Recent Advances in 19Fluorine Magnetic Resonance Imaging with Perfluorocarbon Emulsions. Engineering 2015, 1, 475–489. [Google Scholar] [CrossRef] [PubMed]
  15. Winter, P.M. Perfluorocarbon Nanoparticles: Evolution of a Multimodality and Multifunctional Imaging Agent. Scientifica 2014, 2014, 746574. [Google Scholar] [CrossRef] [PubMed]
  16. Chapelin, F.; Gedaly, R.; Sweeney, Z.; Gossett, L.J. Prognostic Value of Fluorine-19 MRI Oximetry Monitoring in cancer. Mol. Imaging Biol. 2022, 24, 208–219. [Google Scholar] [CrossRef]
  17. Xu, X.; Zhang, R.; Liu, F.; Ping, J.; Wen, X.; Wang, H.; Wang, K.; Sun, X.; Zou, H.; Shen, B.; et al. 19 F MRI in orthotopic cancer model via intratracheal administration of α ν β 3 -targeted perfluorocarbon nanoparticles. Nanomedicine 2018, 13, 2551–2562. [Google Scholar] [CrossRef] [PubMed]
  18. Saini, S.; Vanherwegen, A.-S.; Liang, S.; Verbeke, R.; Korf, H.; Lentacker, I.; de Smedt, S.C.; Gysemans, C.; Himmelreich, U. Fluorine MR Imaging Probes Dynamic Migratory Profiles of Perfluorocarbon-Loaded Dendritic Cells After Streptozotocin-Induced Inflammation. Mol. Imaging Biol. 2022, 24, 321–332. [Google Scholar] [CrossRef] [PubMed]
  19. Tennie, I.K.; Kilbinger, A.F.M. Polymeric 19 F MRI Contrast Agents Prepared by Ring-Opening Metathesis Polymerization/Dihydroxylation. Macromolecules 2020, 53, 10386–10396. [Google Scholar] [CrossRef]
  20. Fu, C.; Demir, B.; Alcantara, S.; Kumar, V.; Han, F.; Kelly, H.G.; Tan, X.; Yu, Y.; Xu, W.; Zhao, J.; et al. Low-Fouling Fluoropolymers for Bioconjugation and In Vivo Tracking. Angew. Chem. Int. Ed. 2020, 59, 4729–4735. [Google Scholar] [CrossRef]
  21. Taylor, N.G.; Chung, S.H.; Kwansa, A.L.; Johnson, R.R.; Teator, A.J.; Milliken, N.J.B.; Koshlap, K.M.; Yingling, Y.G.; Lee, Y.Z.; Leibfarth, F.A. Partially Fluorinated Copolymers as Oxygen Sensitive 19 F MRI Agents. Chem. A Eur. J. 2020, 26, 9982–9990. [Google Scholar] [CrossRef]
  22. Rothemund, S.; Teasdale, I. Preparation of polyphosphazenes: A tutorial review. Chem. Soc. Rev. 2016, 5200, 5200–5215. [Google Scholar] [CrossRef] [PubMed]
  23. Allcock, H.R. The expanding field of polyphosphazene high polymers. Dalton Trans. 2016, 45, 1856–1862. [Google Scholar] [CrossRef] [PubMed]
  24. Strasser, P.; Teasdale, I. Main-Chain Phosphorus-Containing Polymers for Therapeutic Applications. Molecules 2020, 25, 1716. [Google Scholar] [CrossRef] [PubMed]
  25. Alexander, A.K. Polyphosphazenes as Vaccine Adjuvants. In Vaccine Adjuvants and Delivery Systems; John Wiley & Sons, Ltd.: Hoboken, NJ, USA, 2006; pp. 355–378. [Google Scholar]
  26. Wilfert, S.; Henke, H.; Schoefberger, W.; Brüggemann, O.; Teasdale, I. Chain-End-Functionalized Polyphosphazenes via a One-Pot Phosphine-Mediated Living Polymerization. Macromol. Rapid Commun. 2014, 35, 1135–1141. [Google Scholar] [CrossRef]
  27. Strasser, P.; Plavcan, O.; Ajvazi, E.; Henke, H.; Brüggemann, O.; Teasdale, I. Hetero and homo α,ω-chain-end functionalized polyphosphazenes. J. Polym. Sci. 2022, 60, 2000–2007. [Google Scholar] [CrossRef] [PubMed]
  28. Bates, M.C.; Yousaf, A.; Sun, L.; Barakat, M.; Kueller, A. Translational Research and Early Favorable Clinical Results of a Novel Polyphosphazene (Polyzene-F) Nanocoating. Regen. Eng. Transl. Med. 2019, 5, 341–353. [Google Scholar] [CrossRef]
  29. Sharma, R.; Singla, N.; Mehta, S.; Gaba, T.; Rawal, R.; Rao, H.S.; Bhardwaj, T.R. Recent Advances in Polymer Drug Conjugates. MRMC 2015, 15, 751–761. [Google Scholar] [CrossRef]
  30. Lin, M.; Marin, A.; Ellis, B.; Eubanks, L.M.; Andrianov, A.K.; Janda, K.D. Polyphosphazene: A New Adjuvant Platform for Cocaine Vaccine Development. Mol. Pharm. 2022, 19, 3358–3366. [Google Scholar] [CrossRef]
  31. Strasser, P.; Montsch, B.; Weiss, S.; Sami, H.; Kugler, C.; Hager, S.; Schueffl, H.; Mader, R.; Brüggemann, O.; Kowol, C.R.; et al. Degradable Bottlebrush Polypeptides and the Impact of their Architecture on Cell Uptake, Pharmacokinetics, and Biodistribution In Vivo. Small 2023, 19, 2300767. [Google Scholar] [CrossRef]
  32. Wang, B.; Rivard, E.; Manners, I. A New High-Yield Synthesis of Cl3PNSiMe3, a Monomeric Precursor for the Controlled Preparation of High Molecular Weight Polyphosphazenes. Inorg. Chem. 2002, 41, 1690–1691. [Google Scholar] [CrossRef]
  33. Li, Z.; Chen, C.; McCaffrey, M.; Yang, H.; Allcock, H.R. Polyphosphazene Elastomers with Alkoxy and Trifluoroethoxy Side Groups. ACS Appl. Polym. Mater. 2020, 2, 475–480. [Google Scholar] [CrossRef]
  34. Okaru, A.O.; Brunner, T.S.; Ackermann, S.M.; Kuballa, T.; Walch, S.G.; Kohl-Himmelseher, M.; Lachenmeier, D.W. Application of 19 F NMR Spectroscopy for Content Determination of Fluorinated Pharmaceuticals. J. Anal. Methods Chem. 2017, 2017, 9206297. [Google Scholar] [CrossRef] [PubMed]
  35. Rohrer, M.; Bauer, H.; Mintorovitch, J.; Requardt, M.; Weinmann, H.-J. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Investig. Radiol. 2005, 40, 715–724. [Google Scholar] [CrossRef] [PubMed]
  36. Goetschi, S.; Froehlich, J.M.; Chuck, N.C.; Curcio, R.; Runge, V.M.; Andreisek, G.; Nanz, D.; Boss, A. The protein and contrast agent-specific influence of pathological plasma-protein concentration levels on contrast-enhanced magnetic resonance imaging. Investig. Radiol. 2014, 49, 608–619. [Google Scholar] [CrossRef] [PubMed]
  37. Tirotta, I.; Mastropietro, A.; Cordiglieri, C.; Gazzera, L.; Baggi, F.; Baselli, G.; Bruzzone, M.G.; Zucca, I.; Cavallo, G.; Terraneo, G.; et al. A Superfluorinated Molecular Probe for Highly Sensitive in Vivo19 F-MRI. J. Am. Chem. Soc. 2014, 136, 8524–8527. [Google Scholar] [CrossRef] [PubMed]
  38. Mastropietro, A.; de Bernardi, E.; Breschi, G.L.; Zucca, I.; Cametti, M.; Soffientini, C.D.; de Curtis, M.; Terraneo, G.; Metrangolo, P.; Spreafico, R.; et al. Optimization of rapid acquisition with relaxation enhancement (RARE) pulse sequence parameters for ¹⁹F-MRI studies. J. Magn. Reson. Imaging 2014, 40, 162–170. [Google Scholar] [CrossRef] [PubMed]
  39. Colotti, R.; Bastiaansen, J.A.M.; Wilson, A.; Flögel, U.; Gonzales, C.; Schwitter, J.; Stuber, M.; van Heeswijk, R.B. Characterization of perfluorocarbon relaxation times and their influence on the optimization of fluorine-19 MRI at 3 tesla. Magn. Reson. Med. 2017, 77, 2263–2271. [Google Scholar] [CrossRef]
  40. Jirak, D.; Galisova, A.; Kolouchova, K.; Babuka, D.; Hruby, M. Fluorine polymer probes for magnetic resonance imaging: Quo vadis? Magn. Reson. Mater. Phy. 2019, 32, 173–185. [Google Scholar] [CrossRef]
Scheme 1. Schematic synthesis path towards polymers P1 and P2. (a) Macromolecular substitution reaction of poly(dichloro)phosphazene yielding TFE-Propargyl-PPz (P1). (b) Thiol–yne reaction of P1 yielding the final MRI-CA TFE-MESNa-PPz (P2).
Scheme 1. Schematic synthesis path towards polymers P1 and P2. (a) Macromolecular substitution reaction of poly(dichloro)phosphazene yielding TFE-Propargyl-PPz (P1). (b) Thiol–yne reaction of P1 yielding the final MRI-CA TFE-MESNa-PPz (P2).
Jfb 15 00040 sch001
Figure 1. 31P- and 19F-NMR-spectra of P1 and P2 in deuterated acetone and D2O, respectively. (a) 31P-NMR spectra of P1 (black) and P2 (red) showing a stable polyphosphazene and no change in the backbone structure after functionalization. (b) 19F-NMR spectra of P1 (black) and P2 (red) showing successful and stable incorporation of 19F-nuclei.
Figure 1. 31P- and 19F-NMR-spectra of P1 and P2 in deuterated acetone and D2O, respectively. (a) 31P-NMR spectra of P1 (black) and P2 (red) showing a stable polyphosphazene and no change in the backbone structure after functionalization. (b) 19F-NMR spectra of P1 (black) and P2 (red) showing successful and stable incorporation of 19F-nuclei.
Jfb 15 00040 g001
Figure 2. SEC and DLS measurements of TFE-Propargyl-PPz (P1) and TFE-MESNa-PPz (P2). (a) RI-detector traces of SEC measurements of polymers P1 (black) and P2 (red) in DMF. (b) Volume distribution of the DLS measurement of polymer P2 in PBS pH 7.4.
Figure 2. SEC and DLS measurements of TFE-Propargyl-PPz (P1) and TFE-MESNa-PPz (P2). (a) RI-detector traces of SEC measurements of polymers P1 (black) and P2 (red) in DMF. (b) Volume distribution of the DLS measurement of polymer P2 in PBS pH 7.4.
Jfb 15 00040 g002
Figure 3. Quantitative evaluation of TFE-MESNa-PPz P2. (a,b) 19F-MRI FLASH-sequence images of P2 in three concentrations in PBS (a) (4.47 mM, 7.42 mM and 11.1 mM) and in serum (b) (FBS, 3.8 mM, 7.4 mM, 11.1 mM and 16.7 mM). Samples are imaged in Eppendorf vials; ROIs were drawn around the axial view of the vials. A separate ROI was selected to evaluate the image noise. (c,d) Mean signal intensity (black) of the samples in PBS (c) and FSB (d) are shown in dependence of the sample concentration. The signal-to-noise ratio of each concentration is depicted, both corresponding to the mean signal intensity (mSI, full red square) and the standard deviation (Std, empty red square) of the signal intensity in the ROIs.
Figure 3. Quantitative evaluation of TFE-MESNa-PPz P2. (a,b) 19F-MRI FLASH-sequence images of P2 in three concentrations in PBS (a) (4.47 mM, 7.42 mM and 11.1 mM) and in serum (b) (FBS, 3.8 mM, 7.4 mM, 11.1 mM and 16.7 mM). Samples are imaged in Eppendorf vials; ROIs were drawn around the axial view of the vials. A separate ROI was selected to evaluate the image noise. (c,d) Mean signal intensity (black) of the samples in PBS (c) and FSB (d) are shown in dependence of the sample concentration. The signal-to-noise ratio of each concentration is depicted, both corresponding to the mean signal intensity (mSI, full red square) and the standard deviation (Std, empty red square) of the signal intensity in the ROIs.
Jfb 15 00040 g003
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Strasser, P.; Schinegger, V.; Friske, J.; Brüggemann, O.; Helbich, T.H.; Teasdale, I.; Pashkunova-Martic, I. Superfluorinated, Highly Water-Soluble Polyphosphazenes as Potential 19F Magnetic Resonance Imaging (MRI) Contrast Agents. J. Funct. Biomater. 2024, 15, 40. https://doi.org/10.3390/jfb15020040

AMA Style

Strasser P, Schinegger V, Friske J, Brüggemann O, Helbich TH, Teasdale I, Pashkunova-Martic I. Superfluorinated, Highly Water-Soluble Polyphosphazenes as Potential 19F Magnetic Resonance Imaging (MRI) Contrast Agents. Journal of Functional Biomaterials. 2024; 15(2):40. https://doi.org/10.3390/jfb15020040

Chicago/Turabian Style

Strasser, Paul, Verena Schinegger, Joachim Friske, Oliver Brüggemann, Thomas H. Helbich, Ian Teasdale, and Irena Pashkunova-Martic. 2024. "Superfluorinated, Highly Water-Soluble Polyphosphazenes as Potential 19F Magnetic Resonance Imaging (MRI) Contrast Agents" Journal of Functional Biomaterials 15, no. 2: 40. https://doi.org/10.3390/jfb15020040

APA Style

Strasser, P., Schinegger, V., Friske, J., Brüggemann, O., Helbich, T. H., Teasdale, I., & Pashkunova-Martic, I. (2024). Superfluorinated, Highly Water-Soluble Polyphosphazenes as Potential 19F Magnetic Resonance Imaging (MRI) Contrast Agents. Journal of Functional Biomaterials, 15(2), 40. https://doi.org/10.3390/jfb15020040

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop